Electrophysiologic effects of the new Class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: Role of dispersion of refractoriness in antiarrhythmic efficacy

Journal of Cardiovascular Electrophysiology

Volumn 7, Issue 9, 1996, Pages 809-827

  Cha, Yongmei ^a   Wales, Alan ^a   Wolf, Paul ^a   Shahrokni, Shahin ^a   Sawhney, Neil ^a   Feld, Gregory K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

atrial flutter; dispersion of refractory period; dofetilide; quinidine

Indexed keywords

DOFETILIDE; QUINIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRUSH TRAUMA; DOG; HEART ATRIUM FLUTTER; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART FUNCTION; HYPOTHESIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0029818721     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1996.tb00594.x     Document Type: Article

References (38)

1. Ruskin J: The cardiac arrhythmia suppression trial (CAST). N Engl J Med 1989;321:386-387.
2. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1088-1093.
3. Hine LK, Laird N, Hewitt P, et al: Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989;262;3037-3040.
4. Feld GK, Chen PS, Nicod P, et al: Possible atrial proarrhythmic effects of encainide and flecainide. Am J Cardiol 1990;66:378-383.
5. Winkle RA, Mason JW, Griffin JC, et al: Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 1981;102:857-864.
6. Nathan AW, Hellestrand KJ, Bexton RS, et al: Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J 1984;107:222-228.
7. Nademanee K, Feld GK, Hendrickson BS, et al: Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985;72:555-564.
8. Senges J, Lengfelder W, Jauernig R, et al: Electrophysiologic testing of therapy with sotalol for sustained ventricular tachycardia. Circulation 1984;69:577-584.
9. Mason JW, Electrophysiologic Study versus Electrocardiographic Monitoring Investigators: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
10. Feld GK, Venaktesh N, Singh BN: Pharmacological conversion and suppression of experimental canine atrial flutter: Differing effects of d-sotalol, quinidine and lidocaine and significance of changes in refractoriness and conduction. Circulation 1986;74:197-204.
11. Suttorp M, Polak P, van't Hof A, et al: Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in patients with paroxysmal atrial fibrillation or atrial flutter. (Abstract) J Am Coll Cardiol 1992;19: 62A.
12. Kowey PR, Friehling TD, Sewter J, et al: Electrophysiologic effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation 1991;83:2067-2075.
13. Feld GK, Shahandeh-Rad F: Activation patterns in experimental canine atrial flutter produced by right atrial crush injury. J Am Coll Card 1992;20:441-451.
14. Feld GK, Shahandeh-Rad F: Mechanisms of double potentials recorded during sustained atrial flutter in the canine right atrial crush-injury model. Circulation 1992;86:628-641.
15. Gwilt M, Arrowsmith JE, Blackburn KJ, et al: UK-68,798, a novel and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991;256:318-324.
16. Gwilt M, Blackburn KJ, Burges RA, et al: Electropharmacology of dofetilide, a new class III agent, in anesthetized dogs. Eur J Pharmacol 1991;215:137-144.
17. Knilans TK, Lathrop DA, Varro A, et al: Rate and concentration dependent effects of UK-68,798, a potent new class III antiarrhythmic, on canine Purkinje fiber action potential duration and Vmax. Br J Pharmacol 1991;103:1568-1572.
18. K blocking drug, UK-68,798: Potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990;16:401-410.
19. Rasmussen H, Dalrymple H, Allen M, et al: Evolving experimental and clinical profile of dofetilide. In Singh BN, Wellens HJJ, Hiraoka M, eds: Electropharmacological Control of Cardiac Arrhythmias: To Delay Conduction or to Prolong Refractoriness? Futura Publishing Company, Inc., Mount Kisco, NY, 1994, pp. 551-568.
20. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992;262:809-817.
21. Salata JJ, Wasserstrom JA: Effects of quinidine on action potentials and ionic currents in isolated canine ventricular myocytes. Circ Res 1988;62:324-337.
22. K activation in guinea pig ventricular myocytes. Circ Res 1988;62:1055-1058.
23. Wang Z, Pelletier LC, Talajic M, et al: Effects of flecainide and quinidine on human atrial action potentials. Role of rate dependence and comparison with guinea pig, rabbit and dog tissues. Circulation 1990;82: 274-283.
24. Hiraoka M, Samada K, Kamano S: Effects of quinidine on plateau currents of quinea-pig ventricular myocytes. J Mol Cell Cardiol 1986;18:1097-1106.
25. Imaizumi Y, Giles WR: Quinidine induced inhibition of transient outward current in cardiac muscle. Am J Physiol 1987;253:H704-H708.
26. Spach MS, Dolber PC, Heidlage JF: Interaction of inhomogeneities of repolarization with anisotropic propagation in dog atria: A mechanism for both preventing and initiating reentry. Circ Res 1989;65:1612-1631.
27. Allessie MA, Bonke FIM, Schopman FJG: Circus movement in rabbit atrial muscle as a mechanism of tachycardia. Circ Res 1976;39:168-177.
28. Schoels W, Kuebler W, Yang H, et al: A unified functional/anatomical substrate for circus movement atrial flutter: Activation and refractory patterns in the canine right atrial enlargement model. J Am Coll Cardiol 1993;21:73-84
29. Spach MS, Dolber PC: Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level human cardiac muscle. Evidence for electrical uncoupling of side-to-side fiber connections with increasing age. Circ Res 1986;58:356-371.
30. Brugada J, Boersma L, Kirchof CJH, et al: Reentrant excitation around a fixed obstacle in uniform anisotropic ventricular myocardium. Circulation 1991;84: 1296-1306.
31. Vaughan Williams EM: Classification of antiarrhythmic drugs. In Sandoe E, Flensted-Jensen E, Olesen K, eds: Cardiac Arrhythmias. Sweden, Astra, Sodertalje, 1971, pp. 449-472.
32. Vaughan Williams EM: A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-147.
33. Rensma PL, Allessie MA, Lammers WJEP, et al: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988;62:395-410.
34. Allessie MA Bonke FIM, Schopman FJG: Circus movement in rabbit atrial muscle as a mechanisms of tachycardia. Circ Res 1977;41:9-18.
35. Spinelli W, Hoffman BF: Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents. Circ Res 1989;65: 1565-1579.
36. Frame LH, Rhee ER: Spontaneous termination of reentry after one cycle or short nonsustained runs. Role of oscillation and excess dispersion of refractoriness. Circ Res 1991;68:493-502.
37. Spach MS: Anisotropic structural complexities in the genesis of reentrant arrhythmias. Circulation 1991;84: 1447-1449.
38. Boyden PA, Graziano JN: Activation mapping of reentry around an anatomical barrier in the canine atrium: Observations during the action of the class III agent, d-sotalol. J Cardiovasc Electrophysiol 1993;4:266-279.